Literature DB >> 11529926

Amphipathic variable region heavy chain peptides derived from monoclonal human Wegener's anti-PR3 antibodies stimulate lymphocytes from patients with Wegener's granulomatosis and microscopic polyangiitis.

E Peen1, C Malone, C Myers, R C Williams, A B Peck, E Csernok, W L Gross, R Staud.   

Abstract

Amphipathic variable-region heavy chain 11-mer peptides from monoclonal human IgM antiproteinase-3 antibodies were studied for peripheral blood lymphocyte stimulation in 21 patients with Wegener's granulomatosis (WG) or microscopic polyangiitis (MPA), connective tissue disease controls and normal control subjects. Positive T-cell activation was observed in most experiments with WG patients' lymphocytes using amphipathic VH-region peptides from four different human monoclonal anti-PR3 antibodies. Control peptides of the same length but without amphipathic characteristics along with other amphipathic peptides not derived from monoclonal anti-PR3 sequence were employed as controls. No significant lymphocyte stimulation was observed with normal controls, but positive stimulation with amphipathic VH peptides was also recorded in other connective tissue disease controls mainly patients with rheumatoid arthritis. Amphipathic peptides not derived from anti-PR3 sequence did not stimulate WG lymphocytes. Our findings indicate that lymphocyte reactivity as an element of cell-mediated immunity may be activated by amphipathic VH-region amino acid sequences of autoantibodies which are themselves associated with diseases such as WG.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11529926      PMCID: PMC1906128          DOI: 10.1046/j.1365-2249.2001.01482.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  35 in total

1.  Incidence, target antigens, and clinical implications of antineutrophil cytoplasmic antibodies in rheumatoid arthritis.

Authors:  M G Braun; E Csernok; W H Schmitt; W L Gross
Journal:  J Rheumatol       Date:  1996-05       Impact factor: 4.666

2.  Antineutrophil cytoplasmic antibodies induce monocyte IL-8 release. Role of surface proteinase-3, alpha1-antitrypsin, and Fcgamma receptors.

Authors:  D R Ralston; C B Marsh; M P Lowe; M D Wewers
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

3.  Structural analysis of human antibodies to proteinase 3 from patients with Wegener granulomatosis.

Authors:  J Sibilia; K Benlagha; P Vanhille; P Ronco; J C Brouet; X Mariette
Journal:  J Immunol       Date:  1997-07-15       Impact factor: 5.422

Review 4.  Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiological potential.

Authors:  C G Kallenberg; E Brouwer; J J Weening; J W Tervaert
Journal:  Kidney Int       Date:  1994-07       Impact factor: 10.612

5.  Immunopathological studies of polyarteritis nodosa and Wegener's granulomatosis: a report of 43 patients with 51 renal biopsies.

Authors:  P Ronco; P Verroust; F Mignon; O Kourilsky; P Vanhille; A Meyrier; J P Mery; L Morel-Maroger
Journal:  Q J Med       Date:  1983

6.  Incidence and disease associations of a proteinase 3-antineutrophil cytoplasmic antibody idiotype (5/7 Id) whose antiidiotype inhibits proteinase 3-antineutrophil cytoplasmic antibody antigen binding activity.

Authors:  H P Strunz; E Csernok; W L Gross
Journal:  Arthritis Rheum       Date:  1997-01

7.  Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells.

Authors:  J Molldrem; S Dermime; K Parker; Y Z Jiang; D Mavroudis; N Hensel; P Fukushima; A J Barrett
Journal:  Blood       Date:  1996-10-01       Impact factor: 22.113

8.  Antineutrophil cytoplasmic antibodies in rheumatoid arthritis. Characterization and clinical correlations.

Authors:  A H Mulder; G Horst; M A van Leeuwen; P C Limburg; C G Kallenberg
Journal:  Arthritis Rheum       Date:  1993-08

9.  Occurrence of antineutrophil cytoplasmic and antineutrophil (peri)nuclear antibodies in rheumatoid arthritis.

Authors:  X Bosch; J Llena; A Collado; J Font; E Mirapeix; M Ingelmo; J Muñoz-Gómez; A Urbano-Márquez
Journal:  J Rheumatol       Date:  1995-11       Impact factor: 4.666

Review 10.  Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years.

Authors:  A S Fauci; B F Haynes; P Katz; S M Wolff
Journal:  Ann Intern Med       Date:  1983-01       Impact factor: 25.391

View more
  1 in total

1.  In Silico Prediction Analysis of Idiotope-Driven T-B Cell Collaboration in Multiple Sclerosis.

Authors:  Rune A Høglund; Andreas Lossius; Jorunn N Johansen; Jane Homan; Jūratė Šaltytė Benth; Harlan Robins; Bjarne Bogen; Robert D Bremel; Trygve Holmøy
Journal:  Front Immunol       Date:  2017-10-02       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.